董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Gillard | 男 | Director, President and Chief Executive Officer | -- | 113.90万美元 | 1495.00 | 2026-05-01 |
| Tom Lindsay | 男 | Independent Director | -- | 5.20万美元 | 72.92 | 2026-05-01 |
| Andrew Omidvar | 男 | Independent Director | -- | 5.10万美元 | 72.92 | 2026-05-01 |
| Ronan O'Caoimh | 男 | Director | 71 | 6.00万美元 | 1724.67 | 2026-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Gillard | 男 | Director, President and Chief Executive Officer | -- | 113.90万美元 | 1495.00 | 2026-05-01 |
| Matthew Wictome | 男 | Vice President of Quality and Regulatory Affairs | -- | 未披露 | 未持股 | 2026-05-01 |
| Susan O'Connor | 女 | Interim Chief Financial Officer | -- | 未披露 | 未持股 | 2026-05-01 |
| Gary Keating | 男 | Chief Technology Officer | -- | 未披露 | 未持股 | 2026-05-01 |
| Eibhlín Kelly | -- | Chief Information Officer | -- | 未披露 | 未持股 | 2026-05-01 |
| Colm Molloy | 男 | Group Director of Human Resources and Culture | -- | 未披露 | 未持股 | 2026-05-01 |
| Jerry Lydon | 男 | Head of North America Commercial | -- | 未披露 | 未持股 | 2026-05-01 |
| Jim Walsh | 男 | Executive Director of Business Development | 68 | 4.80万美元 | 272.28 | 2026-05-01 |
董事简历
中英对照 | 中文 | 英文- John Gillard
-
John Gillard，于2020年11月加入三一生物科技，担任首席财务官、董事会秘书，并被董事会任命为执行董事。Gillard先生于2023年12月担任三一生物科技的首席执行官兼总裁。吉拉德既是一名特许会计师，也是一名特许税务顾问，曾在普华永道接受培训。在加入三一生物科技之前，Gillard先生曾担任多个高级财务职务，包括2012年至2016年在Alphabet Inc./Google任职，以及2016年11月至2020年5月在ION Investment Group任职。从2020年6月到2020年11月，吉拉德先生还担任商业顾问。Gillard先生拥有爱尔兰国立大学戈尔韦分校的商业学士学位和都柏林大学学院的会计学硕士学位。
John Gillard,joined Trinity Biotech in November 2020 as Chief Financial Officer, Secretary to the Board of Directors and was appointed to the Board as Executive Director. Mr. Gillard assumed the role of CEO and President of Trinity Biotech in December 2023. Mr. Gillard is both a Chartered Accountant and Chartered Tax Advisor, having trained at PWC. Prior to joining Trinity Biotech, Mr. Gillard held a number of senior financial roles including from 2012 to 2016 at Alphabet Inc./Google, and from Nov 2016 to May 2020 at ION Investment Group. From June 2020 until November 2020, Mr. Gillard also acted as a business consultant. Mr. Gillard holds a Bachelor of Commerce degree from the National University of Ireland Galway and a Masters degree in Accounting from University College Dublin. - John Gillard，于2020年11月加入三一生物科技，担任首席财务官、董事会秘书，并被董事会任命为执行董事。Gillard先生于2023年12月担任三一生物科技的首席执行官兼总裁。吉拉德既是一名特许会计师，也是一名特许税务顾问，曾在普华永道接受培训。在加入三一生物科技之前，Gillard先生曾担任多个高级财务职务，包括2012年至2016年在Alphabet Inc./Google任职，以及2016年11月至2020年5月在ION Investment Group任职。从2020年6月到2020年11月，吉拉德先生还担任商业顾问。Gillard先生拥有爱尔兰国立大学戈尔韦分校的商业学士学位和都柏林大学学院的会计学硕士学位。
- John Gillard,joined Trinity Biotech in November 2020 as Chief Financial Officer, Secretary to the Board of Directors and was appointed to the Board as Executive Director. Mr. Gillard assumed the role of CEO and President of Trinity Biotech in December 2023. Mr. Gillard is both a Chartered Accountant and Chartered Tax Advisor, having trained at PWC. Prior to joining Trinity Biotech, Mr. Gillard held a number of senior financial roles including from 2012 to 2016 at Alphabet Inc./Google, and from Nov 2016 to May 2020 at ION Investment Group. From June 2020 until November 2020, Mr. Gillard also acted as a business consultant. Mr. Gillard holds a Bachelor of Commerce degree from the National University of Ireland Galway and a Masters degree in Accounting from University College Dublin.
- Tom Lindsay
-
Tom Lindsay，于2022年10月加入董事会，担任非执行董事。Lindsay先生在全球医疗诊断行业拥有超过35年的销售和营销领导经验，曾担任Alere Inc（现为雅培公司）非洲业务总裁多年。最近，林赛先生为几家国际体外诊断企业提供咨询服务。他目前担任Genedrive plc的非执行董事，Genedrive plc是一家快速、低成本的分子诊断平台，用于识别和治疗一系列传染病。
Tom Lindsay,joined the Board as a non-executive director in October 2022. Mr. Lindsay has more than 35 years of sales and marketing leadership experience in the global medical diagnostics industry and was President of Alere Inc's (now Abbotts's) business in Africa for many years. Most recently, Mr Lindsay has provided consultancy services to several international in vitro diagnostics businesses. He currently serves as a non-executive director for Genedrive plc, a rapid, low-cost molecular diagnostics platform for the identification and treatment of a selection of infectious diseases. - Tom Lindsay，于2022年10月加入董事会，担任非执行董事。Lindsay先生在全球医疗诊断行业拥有超过35年的销售和营销领导经验，曾担任Alere Inc（现为雅培公司）非洲业务总裁多年。最近，林赛先生为几家国际体外诊断企业提供咨询服务。他目前担任Genedrive plc的非执行董事，Genedrive plc是一家快速、低成本的分子诊断平台，用于识别和治疗一系列传染病。
- Tom Lindsay,joined the Board as a non-executive director in October 2022. Mr. Lindsay has more than 35 years of sales and marketing leadership experience in the global medical diagnostics industry and was President of Alere Inc's (now Abbotts's) business in Africa for many years. Most recently, Mr Lindsay has provided consultancy services to several international in vitro diagnostics businesses. He currently serves as a non-executive director for Genedrive plc, a rapid, low-cost molecular diagnostics platform for the identification and treatment of a selection of infectious diseases.
- Andrew Omidvar
-
Andrew Omidvar，2023年12月加入三一生物科技董事会。拥有超过25年的经验，带领跨职能团队在多个行业提供尖端技术解决方案。他带来了医疗器械行业基于数据和AI系统的开发和产品支持经验。最近，Omidvar博士担任飞利浦政府研发和企业副总裁。
Andrew Omidvar,joined the Board of Trinity Biotech in December 2023. With over twenty-five years of experience leading cross-functional teams to deliver cutting edge technology solutions in a variety of industries. Most recently Dr. Omidvar served as Vice President of Government R&D and Enterprise for Philips. - Andrew Omidvar，2023年12月加入三一生物科技董事会。拥有超过25年的经验，带领跨职能团队在多个行业提供尖端技术解决方案。他带来了医疗器械行业基于数据和AI系统的开发和产品支持经验。最近，Omidvar博士担任飞利浦政府研发和企业副总裁。
- Andrew Omidvar,joined the Board of Trinity Biotech in December 2023. With over twenty-five years of experience leading cross-functional teams to deliver cutting edge technology solutions in a variety of industries. Most recently Dr. Omidvar served as Vice President of Government R&D and Enterprise for Philips.
- Ronan O'Caoimh
-
Ronan O'Caoimh，董事长、首席执行官；在1992年6月参与创办Trinity Biotech，并担任首席财务官，直到1994年3月，他成为首席执行官。1995年5月，他还当选为董事长。2007年11月，本公司首席执行官和董事长的职务分离，他于是担任执行董事长。2008年10月，公司首席执行官辞职，他重新担任首席执行官、董事长。加入Trinity Biotech之前，他是爱尔兰诊断公司Noctech Limited的总经理；1988年起，担任其财务总监，直到至1991年1月成为总经理。他在University College Dublin获得商业学士学位，是爱尔兰Institute of Chartered Accountants的资深会员。2011年3月30日，他担任本公司首席执行官的服务协议终止，取而代之的是与Darnick Limited的服务协议。
Ronan O'Caoimh,co-founded Trinity Biotech in June 1992 and acted as Chief Financial Officer until March 1994 when he became Chief Executive Officer. He was also elected Chairman in May 1995. On May 3, 2022, Mr. O'Caoimh stepped down as Chairman and was replaced as Chairman by Seon Kyu Jeon. On October 3, 2022, Mr O'Caoimh stepped down as Chief Executive Officer. Prior to joining Trinity Biotech, Mr O'Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr O'Caoimh was Finance Director of Noctech Limited from 1988 until January 1991 when he became Managing Director. Mr O'Caoimh holds a Bachelor of Commerce degree from University College Dublin. On March 30, 2011, the service agreement with Ronan O'Caoimh as Chief Executive Officer was terminated and replaced by a management agreement with Darnick Company. This arrangement ceased with effect from December 31, 2018, with Ronan O'Caoimh returning as an employee of the Company. - Ronan O'Caoimh，董事长、首席执行官；在1992年6月参与创办Trinity Biotech，并担任首席财务官，直到1994年3月，他成为首席执行官。1995年5月，他还当选为董事长。2007年11月，本公司首席执行官和董事长的职务分离，他于是担任执行董事长。2008年10月，公司首席执行官辞职，他重新担任首席执行官、董事长。加入Trinity Biotech之前，他是爱尔兰诊断公司Noctech Limited的总经理；1988年起，担任其财务总监，直到至1991年1月成为总经理。他在University College Dublin获得商业学士学位，是爱尔兰Institute of Chartered Accountants的资深会员。2011年3月30日，他担任本公司首席执行官的服务协议终止，取而代之的是与Darnick Limited的服务协议。
- Ronan O'Caoimh,co-founded Trinity Biotech in June 1992 and acted as Chief Financial Officer until March 1994 when he became Chief Executive Officer. He was also elected Chairman in May 1995. On May 3, 2022, Mr. O'Caoimh stepped down as Chairman and was replaced as Chairman by Seon Kyu Jeon. On October 3, 2022, Mr O'Caoimh stepped down as Chief Executive Officer. Prior to joining Trinity Biotech, Mr O'Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr O'Caoimh was Finance Director of Noctech Limited from 1988 until January 1991 when he became Managing Director. Mr O'Caoimh holds a Bachelor of Commerce degree from University College Dublin. On March 30, 2011, the service agreement with Ronan O'Caoimh as Chief Executive Officer was terminated and replaced by a management agreement with Darnick Company. This arrangement ceased with effect from December 31, 2018, with Ronan O'Caoimh returning as an employee of the Company.
高管简历
中英对照 | 中文 | 英文- John Gillard
John Gillard，于2020年11月加入三一生物科技，担任首席财务官、董事会秘书，并被董事会任命为执行董事。Gillard先生于2023年12月担任三一生物科技的首席执行官兼总裁。吉拉德既是一名特许会计师，也是一名特许税务顾问，曾在普华永道接受培训。在加入三一生物科技之前，Gillard先生曾担任多个高级财务职务，包括2012年至2016年在Alphabet Inc./Google任职，以及2016年11月至2020年5月在ION Investment Group任职。从2020年6月到2020年11月，吉拉德先生还担任商业顾问。Gillard先生拥有爱尔兰国立大学戈尔韦分校的商业学士学位和都柏林大学学院的会计学硕士学位。
John Gillard,joined Trinity Biotech in November 2020 as Chief Financial Officer, Secretary to the Board of Directors and was appointed to the Board as Executive Director. Mr. Gillard assumed the role of CEO and President of Trinity Biotech in December 2023. Mr. Gillard is both a Chartered Accountant and Chartered Tax Advisor, having trained at PWC. Prior to joining Trinity Biotech, Mr. Gillard held a number of senior financial roles including from 2012 to 2016 at Alphabet Inc./Google, and from Nov 2016 to May 2020 at ION Investment Group. From June 2020 until November 2020, Mr. Gillard also acted as a business consultant. Mr. Gillard holds a Bachelor of Commerce degree from the National University of Ireland Galway and a Masters degree in Accounting from University College Dublin.- John Gillard，于2020年11月加入三一生物科技，担任首席财务官、董事会秘书，并被董事会任命为执行董事。Gillard先生于2023年12月担任三一生物科技的首席执行官兼总裁。吉拉德既是一名特许会计师，也是一名特许税务顾问，曾在普华永道接受培训。在加入三一生物科技之前，Gillard先生曾担任多个高级财务职务，包括2012年至2016年在Alphabet Inc./Google任职，以及2016年11月至2020年5月在ION Investment Group任职。从2020年6月到2020年11月，吉拉德先生还担任商业顾问。Gillard先生拥有爱尔兰国立大学戈尔韦分校的商业学士学位和都柏林大学学院的会计学硕士学位。
- John Gillard,joined Trinity Biotech in November 2020 as Chief Financial Officer, Secretary to the Board of Directors and was appointed to the Board as Executive Director. Mr. Gillard assumed the role of CEO and President of Trinity Biotech in December 2023. Mr. Gillard is both a Chartered Accountant and Chartered Tax Advisor, having trained at PWC. Prior to joining Trinity Biotech, Mr. Gillard held a number of senior financial roles including from 2012 to 2016 at Alphabet Inc./Google, and from Nov 2016 to May 2020 at ION Investment Group. From June 2020 until November 2020, Mr. Gillard also acted as a business consultant. Mr. Gillard holds a Bachelor of Commerce degree from the National University of Ireland Galway and a Masters degree in Accounting from University College Dublin.
- Matthew Wictome
马修·威克托姆，于2025年1月被任命担任这一职务。他还是Datod Consulting的创始人和董事总经理，专门致力于打造世界级的优质组织。Wictome博士在医疗保健领域拥有超过30年的经验，曾在强生、Ortho Clinical诊断公司和英国健康保护局担任研发和质量方面的领导职务。他拥有巴斯大学生物化学学士学位、南安普顿大学生物化学博士学位，以及布里斯托大学高管发展项目战略、变革和领导力理学硕士学位。Wictome博士也是《Transforming Quality Organizations：A Practical Guide（Business Expert Press，New York，April 2023）》一书的合著者。
Matthew Wictome,was appointed to this role in January 2025. He is also the Founder and Managing Director of Datod Consulting, specialising in building world-class Quality organisations. With over 30 years of experience in the healthcare sector, Dr. Wictome has held leadership roles in R&D and Quality at Johnson & Johnson, Ortho Clinical Diagnostics, and the UK's Health Protection Agency. He holds a BSc in Biochemistry from the University of Bath, a PhD in Biochemistry from the University of Southampton, and an MSc in Strategy, Change and Leadership from the University of Bristol's Executive Development Program. Dr. Wictome is also the co-author of Transforming Quality Organizations: A Practical Guide (Business Expert Press, New York, April 2023).- 马修·威克托姆，于2025年1月被任命担任这一职务。他还是Datod Consulting的创始人和董事总经理，专门致力于打造世界级的优质组织。Wictome博士在医疗保健领域拥有超过30年的经验，曾在强生、Ortho Clinical诊断公司和英国健康保护局担任研发和质量方面的领导职务。他拥有巴斯大学生物化学学士学位、南安普顿大学生物化学博士学位，以及布里斯托大学高管发展项目战略、变革和领导力理学硕士学位。Wictome博士也是《Transforming Quality Organizations：A Practical Guide（Business Expert Press，New York，April 2023）》一书的合著者。
- Matthew Wictome,was appointed to this role in January 2025. He is also the Founder and Managing Director of Datod Consulting, specialising in building world-class Quality organisations. With over 30 years of experience in the healthcare sector, Dr. Wictome has held leadership roles in R&D and Quality at Johnson & Johnson, Ortho Clinical Diagnostics, and the UK's Health Protection Agency. He holds a BSc in Biochemistry from the University of Bath, a PhD in Biochemistry from the University of Southampton, and an MSc in Strategy, Change and Leadership from the University of Bristol's Executive Development Program. Dr. Wictome is also the co-author of Transforming Quality Organizations: A Practical Guide (Business Expert Press, New York, April 2023).
- Susan O'Connor
Susan O'Connor，于2025年4月加入公司，担任Trinity Biotech Plc临时首席财务官。她是普华永道培训的特许会计师，在爱尔兰、英国、加拿大和澳大利亚的技术、高科技制造、健康和生命科学、专业服务和金融服务领域拥有超过20年的多元化国际经验。在加入三一生物科技之前，O'Connor女士是Glantus Holdings PLC的首席财务官，此前她曾在该公司成功IPO，通过贸易出售和收购后整合引领其过渡。她曾在上市公司和私营公司担任首席财务官和咨询职务，支持IPO、并购交易、运营重组和扩大规模。O'Connor女士拥有都柏林城市大学会计学IT管理理学硕士学位和爱尔兰特许会计师的战略金融和分析文凭。
Susan O'Connor,joined the company in April 2025 as Trinity Biotech Plc CFO on an interim basis. She is a PwC-trained Chartered Accountant with over 20 years of diverse international experience in Technology, High-tech manufacturing, Health and Life Sciences, Professional Services and Financial Services sectors in Ireland, UK, Canada and Australia. Prior to joining Trinity Biotech, Ms. O'Connor was CFO of Glantus Holdings plc, where, having worked previously on its successful IPO, she led its transition through a trade sale and post-acquisition integration. She has held CFO and consulting roles in both public and private companies, supporting IPOs, M&A transactions, and operational restructurings and scale-ups. Ms. O'Connor holds a Master of Science in the Management of IT in Accounting from Dublin City University and a Diploma in Strategic Finance and Analytics from Chartered Accountants Ireland.- Susan O'Connor，于2025年4月加入公司，担任Trinity Biotech Plc临时首席财务官。她是普华永道培训的特许会计师，在爱尔兰、英国、加拿大和澳大利亚的技术、高科技制造、健康和生命科学、专业服务和金融服务领域拥有超过20年的多元化国际经验。在加入三一生物科技之前，O'Connor女士是Glantus Holdings PLC的首席财务官，此前她曾在该公司成功IPO，通过贸易出售和收购后整合引领其过渡。她曾在上市公司和私营公司担任首席财务官和咨询职务，支持IPO、并购交易、运营重组和扩大规模。O'Connor女士拥有都柏林城市大学会计学IT管理理学硕士学位和爱尔兰特许会计师的战略金融和分析文凭。
- Susan O'Connor,joined the company in April 2025 as Trinity Biotech Plc CFO on an interim basis. She is a PwC-trained Chartered Accountant with over 20 years of diverse international experience in Technology, High-tech manufacturing, Health and Life Sciences, Professional Services and Financial Services sectors in Ireland, UK, Canada and Australia. Prior to joining Trinity Biotech, Ms. O'Connor was CFO of Glantus Holdings plc, where, having worked previously on its successful IPO, she led its transition through a trade sale and post-acquisition integration. She has held CFO and consulting roles in both public and private companies, supporting IPOs, M&A transactions, and operational restructurings and scale-ups. Ms. O'Connor holds a Master of Science in the Management of IT in Accounting from Dublin City University and a Diploma in Strategic Finance and Analytics from Chartered Accountants Ireland.
- Gary Keating
Gary Keating，2022年10月加入Trinity Biotech Plc。Keating博士毕业于约旦镇阿尔斯特大学，获得应用生化科学学士学位，并在DCU的Richard O'Kennedy教授的应用生物化学组中追求他对生物传感器的兴趣，在那里他致力于开发用于检测小药物分子的基于抗体的光学生物传感器。Keating博士于1998年获得博士学位；他博士学位的外部考官是George Guilbault教授，他描述了第一个安培葡萄糖电极。在加入三一生物科技之前，Keating博士于2014年10月至2022年8月期间在Hibergene Diagnostics Ltd.担任CTO职务。在加入Hibergene之前，Keating博士在初创公司和跨国诊断公司担任过一系列技术领导职务，包括Abbott Diagnostics的转让经理和Diasorin Ireland的研发经理。
Gary Keating,joined Trinity Biotech Plc in October 2022. Dr Keating graduated from the University of Ulster at Jordanstown with a BSc in Applied Biochemical Sciences and pursued his interest in biosensors in Prof Richard O'Kennedy's Applied Biochemistry group at DCU, where he worked on the development of antibody-based optical biosensors for the detection of small drug molecules. Dr Keating earned his PhD in 1998; the external examiner for his doctorate was Prof George Guilbault, who described the first amperometric glucose electrode. Prior to joining Trinity Biotech, Dr Keating held the position of CTO with Hibergene Diagnostics Ltd. from October 2014 to August 2022. Previous to Hibergene, Dr Keating held a range of technical leadership roles in start-up and multinational diagnostics companies, including Transfer Manager at Abbott Diagnostics and R&D Manager at Diasorin Ireland.- Gary Keating，2022年10月加入Trinity Biotech Plc。Keating博士毕业于约旦镇阿尔斯特大学，获得应用生化科学学士学位，并在DCU的Richard O'Kennedy教授的应用生物化学组中追求他对生物传感器的兴趣，在那里他致力于开发用于检测小药物分子的基于抗体的光学生物传感器。Keating博士于1998年获得博士学位；他博士学位的外部考官是George Guilbault教授，他描述了第一个安培葡萄糖电极。在加入三一生物科技之前，Keating博士于2014年10月至2022年8月期间在Hibergene Diagnostics Ltd.担任CTO职务。在加入Hibergene之前，Keating博士在初创公司和跨国诊断公司担任过一系列技术领导职务，包括Abbott Diagnostics的转让经理和Diasorin Ireland的研发经理。
- Gary Keating,joined Trinity Biotech Plc in October 2022. Dr Keating graduated from the University of Ulster at Jordanstown with a BSc in Applied Biochemical Sciences and pursued his interest in biosensors in Prof Richard O'Kennedy's Applied Biochemistry group at DCU, where he worked on the development of antibody-based optical biosensors for the detection of small drug molecules. Dr Keating earned his PhD in 1998; the external examiner for his doctorate was Prof George Guilbault, who described the first amperometric glucose electrode. Prior to joining Trinity Biotech, Dr Keating held the position of CTO with Hibergene Diagnostics Ltd. from October 2014 to August 2022. Previous to Hibergene, Dr Keating held a range of technical leadership roles in start-up and multinational diagnostics companies, including Transfer Manager at Abbott Diagnostics and R&D Manager at Diasorin Ireland.
- Eibhlín Kelly
Eibhl í n Kelly，自2015年9月起担任首席信息官
Eibhlín Kelly,has served as Chief Information Officer since September 2015.- Eibhl í n Kelly，自2015年9月起担任首席信息官
- Eibhlín Kelly,has served as Chief Information Officer since September 2015.
- Colm Molloy
Colm Molloy，拥有超30年的人力资源和培训经验，于2021年1月加入三一生物科技。在加入三一生物科技之前，他于2019年6月至2020年7月在生物技术公司Nuritas担任人力资源主管。他此前担任的职务包括2015年3月至2019年6月在Storm Technology担任人力资源总监，2011年至2015年在Grant Thornton Ireland担任人力资源主管。他是英国特许人事与发展协会（CIPD）的会员，也是爱尔兰市场营销协会的毕业生。
Colm Molloy,has over 30 years Human Resources and training experience and joined Trinity Biotech in January 2021. Prior to joining Trinity Biotech, he served as Head of Human Resources with Nuritas, a biotechnology company from June 2019 to July 2020. His previous roles included HR Director at Storm Technology from March 2015 to June 2019 and Head of Human Resources at Grant Thornton Ireland from 2011 to 2015. He is a Fellow of the Chartered Institute of Personnel and Development (CIPD) and a Graduate of the Marketing Institute of Ireland.- Colm Molloy，拥有超30年的人力资源和培训经验，于2021年1月加入三一生物科技。在加入三一生物科技之前，他于2019年6月至2020年7月在生物技术公司Nuritas担任人力资源主管。他此前担任的职务包括2015年3月至2019年6月在Storm Technology担任人力资源总监，2011年至2015年在Grant Thornton Ireland担任人力资源主管。他是英国特许人事与发展协会（CIPD）的会员，也是爱尔兰市场营销协会的毕业生。
- Colm Molloy,has over 30 years Human Resources and training experience and joined Trinity Biotech in January 2021. Prior to joining Trinity Biotech, he served as Head of Human Resources with Nuritas, a biotechnology company from June 2019 to July 2020. His previous roles included HR Director at Storm Technology from March 2015 to June 2019 and Head of Human Resources at Grant Thornton Ireland from 2011 to 2015. He is a Fellow of the Chartered Institute of Personnel and Development (CIPD) and a Graduate of the Marketing Institute of Ireland.
- Jerry Lydon
Jerry Lydon在诊断和医疗保健领域拥有丰富的商业领导经验，在提高销售执行、管理分销商和直销渠道方面有着良好的业绩记录。在他的职位上，Lydon先生将监督Trinity的北美商业组织，负责整个核心诊断产品组合的商业执行。
Jerry Lydon,has extensive commercial leadership experience in diagnostics and healthcare, with a strong track record of improving sales execution, managing distributor and direct sales channels. In his role, Mr. Lydon will oversee Trinity's North America commercial organisation, with responsibility for commercial execution across the core diagnostics portfolio.- Jerry Lydon在诊断和医疗保健领域拥有丰富的商业领导经验，在提高销售执行、管理分销商和直销渠道方面有着良好的业绩记录。在他的职位上，Lydon先生将监督Trinity的北美商业组织，负责整个核心诊断产品组合的商业执行。
- Jerry Lydon,has extensive commercial leadership experience in diagnostics and healthcare, with a strong track record of improving sales execution, managing distributor and direct sales channels. In his role, Mr. Lydon will oversee Trinity's North America commercial organisation, with responsibility for commercial execution across the core diagnostics portfolio.
- Jim Walsh
Jim Walsh，1995年10月第一次加入Trinity Biotech ，担任首席运营官。2007年，他辞去该职，成为本公司的非执行董事。2010年10月，他再次加入本公司，担任首席科学官。加入Trinity Biotech 之前，他是Cambridge Diagnostics Ireland Limited CDIL的总经理；他从1987年起任职于CDIL。加入CDIL之前，他是Fleming GmbH的研发经理。他在University College Galway获得化学博士学位。
Jim Walsh,initially joined Trinity Biotech in October 1995 as Chief Operations Officer. Dr Walsh resigned from the role of Chief Operations Officer in 2007 to become a Director of the Company. In October 2010, Dr Walsh rejoined the Company as Chief Scientific Officer. Dr Walsh transferred from this position in 2015 and now provides strategic advice and technical diligence support, on a part time basis, with regards to the Company's business development activities. Prior to joining Trinity Biotech, Dr Walsh was Managing Director of Cambridge Diagnostics Ireland Limited ("CDIL"). He was employed with CDIL since 1987. Before joining CDIL he worked with Fleming GmbH as Research & Development Manager. Dr. Walsh is a director of a number of private Irish companies in the biotechnology and diagnostics sector, including EPONA Biotech since 2016, AllWorth Diagnostics since 2019 and AbacusLabs since 2020. Dr Walsh holds a PhD degree in Chemistry from University College Galway.- Jim Walsh，1995年10月第一次加入Trinity Biotech ，担任首席运营官。2007年，他辞去该职，成为本公司的非执行董事。2010年10月，他再次加入本公司，担任首席科学官。加入Trinity Biotech 之前，他是Cambridge Diagnostics Ireland Limited CDIL的总经理；他从1987年起任职于CDIL。加入CDIL之前，他是Fleming GmbH的研发经理。他在University College Galway获得化学博士学位。
- Jim Walsh,initially joined Trinity Biotech in October 1995 as Chief Operations Officer. Dr Walsh resigned from the role of Chief Operations Officer in 2007 to become a Director of the Company. In October 2010, Dr Walsh rejoined the Company as Chief Scientific Officer. Dr Walsh transferred from this position in 2015 and now provides strategic advice and technical diligence support, on a part time basis, with regards to the Company's business development activities. Prior to joining Trinity Biotech, Dr Walsh was Managing Director of Cambridge Diagnostics Ireland Limited ("CDIL"). He was employed with CDIL since 1987. Before joining CDIL he worked with Fleming GmbH as Research & Development Manager. Dr. Walsh is a director of a number of private Irish companies in the biotechnology and diagnostics sector, including EPONA Biotech since 2016, AllWorth Diagnostics since 2019 and AbacusLabs since 2020. Dr Walsh holds a PhD degree in Chemistry from University College Galway.